JP2008540629A - 非晶形のｖｅｇｆ−ｒ阻害剤を含む医薬組成物 - Google Patents

非晶形のｖｅｇｆ−ｒ阻害剤を含む医薬組成物 Download PDF

Info

Publication number
JP2008540629A
JP2008540629A JP2008511809A JP2008511809A JP2008540629A JP 2008540629 A JP2008540629 A JP 2008540629A JP 2008511809 A JP2008511809 A JP 2008511809A JP 2008511809 A JP2008511809 A JP 2008511809A JP 2008540629 A JP2008540629 A JP 2008540629A
Authority
JP
Japan
Prior art keywords
compound
composition
matrix
amorphous
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008511809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540629A5 (enExample
Inventor
トーマス フリーセン ドワイン
アラン ロレンツ ダグラス
ウェンデル スミス スコット
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2008540629A publication Critical patent/JP2008540629A/ja
Publication of JP2008540629A5 publication Critical patent/JP2008540629A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2008511809A 2005-05-19 2006-05-08 非晶形のｖｅｇｆ−ｒ阻害剤を含む医薬組成物 Withdrawn JP2008540629A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68292805P 2005-05-19 2005-05-19
PCT/IB2006/001295 WO2006123223A1 (en) 2005-05-19 2006-05-08 Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Publications (2)

Publication Number Publication Date
JP2008540629A true JP2008540629A (ja) 2008-11-20
JP2008540629A5 JP2008540629A5 (enExample) 2009-01-08

Family

ID=36933392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511809A Withdrawn JP2008540629A (ja) 2005-05-19 2006-05-08 非晶形のｖｅｇｆ−ｒ阻害剤を含む医薬組成物

Country Status (5)

Country Link
US (1) US20080274192A1 (enExample)
EP (1) EP1885338A1 (enExample)
JP (1) JP2008540629A (enExample)
CA (1) CA2608952A1 (enExample)
WO (1) WO2006123223A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107040A1 (ja) * 2009-03-19 2010-09-23 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP2016507574A (ja) * 2013-02-12 2016-03-10 ベンド・リサーチ・インコーポレーテッドＢｅｎｄ Ｒｅｓｅａｒｃｈ，Ｉｎｃｏｒｐｏｒａｔｅｄ 低水溶性活性物質の固体分散体
JP2016537332A (ja) * 2013-11-22 2016-12-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 非ヌクレオシド逆転写酵素阻害剤の組成物
JP2016204392A (ja) * 2012-09-11 2016-12-08 メディベイション プロステイト セラピューティクス， インコーポレイテッド エンザルタミドの製剤

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070058690A (ko) 2004-11-02 2007-06-08 화이자 인코포레이티드 인다졸 화합물의 제조방법
MX2009010761A (es) † 2007-04-05 2009-10-28 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.
EP2305263B1 (en) * 2007-06-07 2012-09-19 Novartis AG Stabilized amorphous forms of imatinib mesylate
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
MX2014003886A (es) 2011-09-30 2014-05-13 Pfizer Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
WO2013068909A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
ES2946549T3 (es) 2012-01-13 2023-07-20 Xspray Pharma Ab Publ Composición farmacéutica de nilotinib
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104140414B (zh) * 2013-05-07 2018-12-11 江苏豪森药业集团有限公司 阿昔替尼晶型的制备方法
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
CN118286440A (zh) 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
JP2017530950A (ja) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
IL278423B2 (en) 2015-02-26 2024-04-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
KR102013440B1 (ko) * 2015-04-03 2019-08-22 임팩트 테라퓨틱스, 인코포레이티드 Parp 억제제 고체약물제형 및 그 용도
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
CN106467512B (zh) * 2015-08-19 2022-03-11 浙江九洲药业股份有限公司 一种阿西替尼富马酸盐及其结晶形式和制备方法
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2019234581A1 (en) * 2018-06-04 2019-12-12 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of axitinib
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
WO2022000265A1 (zh) * 2020-06-30 2022-01-06 天津理工大学 一种阿西替尼与戊二酸共晶及其制备方法
JP7654346B2 (ja) 2022-03-03 2025-04-01 ファイザー・インク 多重特異性抗体およびその使用
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148542A (en) * 1977-05-27 1978-12-25 Reiichi Yamaga Pharmaceutical composition densistry
JPS59219384A (ja) * 1983-05-30 1984-12-10 Mitsui Norin Kk 天然抗酸化剤の製造方法
US5266319A (en) * 1992-03-18 1993-11-30 National Science Council Tannin derivatives and their use for treatment of hypertension
US5773419A (en) * 1995-03-03 1998-06-30 Falcon; Juan Method of treating cancer with tannic acid
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
PT1469833T (pt) * 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
US20040126448A1 (en) * 2002-08-05 2004-07-01 Nils-Olof Lindberg Sexual dysfunction compounds
WO2004092217A1 (en) * 2003-04-17 2004-10-28 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
AU2005300317A1 (en) * 2004-11-02 2006-05-11 Pfizer Inc. Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107040A1 (ja) * 2009-03-19 2010-09-23 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP2016204392A (ja) * 2012-09-11 2016-12-08 メディベイション プロステイト セラピューティクス， インコーポレイテッド エンザルタミドの製剤
JP2018087206A (ja) * 2012-09-11 2018-06-07 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
JP2016507574A (ja) * 2013-02-12 2016-03-10 ベンド・リサーチ・インコーポレーテッドＢｅｎｄ Ｒｅｓｅａｒｃｈ，Ｉｎｃｏｒｐｏｒａｔｅｄ 低水溶性活性物質の固体分散体
JP2016537332A (ja) * 2013-11-22 2016-12-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 非ヌクレオシド逆転写酵素阻害剤の組成物

Also Published As

Publication number Publication date
US20080274192A1 (en) 2008-11-06
CA2608952A1 (en) 2006-11-23
EP1885338A1 (en) 2008-02-13
WO2006123223A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
JP2008540629A (ja) 非晶形のｖｅｇｆ−ｒ阻害剤を含む医薬組成物
US20230338372A1 (en) Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
CN115243681B (zh) 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
JP4547148B2 (ja) 非晶質薬剤の吸着物の医薬組成物
JP5932848B2 (ja) アモルファス（５−フルオロ−２−メチル−３−キノリン−２−イルメチル−インドール−１−イル）−酢酸
CA2448864C (en) Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
NL2000337A1 (nl) Zouten, voorgeneesmiddelen en formuleringen van 1-[5- (4-amino-7-isopropyl-7H-pyrrool[2,3-D]pyrimidine-5-carbonyl)-2- methoxyfenyl]-3- (2,4-dichloorfenyl)-ureum.
CN108601839B (zh) 用于治疗癌症的Bcl-2抑制剂和MEK抑制剂组合产品
TW200307565A (en) Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
BG107456A (bg) Фармацевтични състави на инхибитори на протеин, пренасящ холестерилов естер
TW201202234A (en) Solid dispersions containing kinase inhibitors
CA2569277A1 (en) Method for treating abnormal cell growth
CZ20033457A3 (cs) Farmaceutická kompozice zahrnující léčiva s nízkou rozpustností a/nebo léčiva citlivá na kyselinu a neutralizované kyselé polymery
JP2011515444A (ja) 固体分散体の調製方法
CN111225662B (zh) 药物组合物和剂型
TWI899133B (zh) 非晶形激酶抑制劑調配物及其使用方法
US20070287719A1 (en) Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
US20230263782A1 (en) Oral formulations and uses thereof
HK40085289B (zh) 固体[(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸
BR122024022974A2 (pt) Dispersões sólidas e composições de 1-(4-bromo-5-(1-etil-7-(metilamino) -2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilureia, usos e processo relacionados
HK1158528B (en) Pharmaceutical formulation 514
NZ614852B2 (en) Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090424

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090424

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110826